This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Vlase, H. Articles by Davies, T. F. Search for Related Content PubMed PubMed Citation Articles by Vlase, H. Articles by Davies, T. F. Pubmed/NCBI databases Gene GEO Profiles HomoloGene UniGene Substance via MeSH

Folding-Dependent Binding of Thyrotropin (TSH) and TSH Receptor Autoantibodies to the Murine TSH Receptor Ectodomain¹

Departments of Medicine and Pharmacology (R.P.M.), Mount Sinai School of Medicine, New York, New York 10029

Address all correspondence and requests for reprints to: Dr. T. F. Davies, Box 1055, Mount Sinai Medical Center, 1 Gustave L. Levy Place, New York, New York 10029.

The mouse TSH receptor ectodomain (mTSHR-ecd) was amplified from murine thyroid complementary DNA and ligated into the pAcGP67B insect cell vector, and the nucleotide sequence was confirmed. Employing a baculovirus-insect cell system, the mTSHR-ecd (amino acids 22–415) was expressed as a fusion protein with the gp67 insect cell signal sequence at the NH₂-terminus and a C-terminal six-histidine tag. Protein expression was assessed by Western blot using a murine monoclonal antibody (recognizing amino acids 22–35) and a rabbit antipeptide antibody (recognizing amino acids 397–415). These antibodies detected two principal species of mTSHR-ecd, one glycosylated (66 kDa) and one nonglycosylated (52 kDa), in cell lysates of infected insect cells. More than 10% of these species were present in a water-soluble (cytosolic) fraction. This fraction was then used to purify, under native conditions, 100-µg amounts of mTSHR-ecd using nickel-nitrilo-triacetic (Ni-NTA) resin chromatography. The purified cytosolic mTSHR-ecd migrated as a homogeneous 66-kDa band visible on Coomassie blue-stained gels and was confirmed by Western blotting. We also purified the mTSHR-ecd from total cell lysates under denaturing conditions, followed by "in vitro" refolding on the Ni-NTA column. Under these conditions, milligram amounts of soluble mTSHR-ecd were obtained. This material consisted primarily of the 66-kDa glycosylated form, but in addition contained four or five lower molecular mass, partially glycosylated intermediates and the 52-kDa nonglycosylated form. Deglycosylation with either endoglycosidase F or H, reduced all mTSHR-ecd glycosylated species to a 52-kDa nonglycosylated form. Both the cytosolic and refolded mTSHR-ecd preparations inhibited the binding of [¹²⁵I]TSH to the full-length human TSHR expressed in Chinese hamster ovary cells in a dose-dependent manner, with similar affinities. The affinity of such interactions was 3 orders of magnitude less than observed with native porcine TSHR and was further reduced by unfolding the mTSHR-ecd preparations. The cytosolic and refolded mTSHR-ecd were also recognized by hTSHR autoantibodies in the serum of patients with hyperthyroid Graves’ disease. Such autoantibody binding to mTSHR-ecd was also markedly reduced by unfolding the antigen.

These results demonstrated the successful production of large quantities of well characterized, biologically active, mTSHR-ecd antigen. In addition, the data showed that although the ectodomain of the mTSHR bound TSH, intact holoreceptor may be required for high affinity ligand binding. Whether the transmembrane region is required for direct ligand binding, as seen for other G protein-linked receptors, or whether it is needed to stabilize the ligand binding to the ectodomain and maintain a correctly folded state, remains unclear.

This article has been cited by other articles:

				S. M. McLachlan, Y. Nagayama, and B. Rapoport Insight into Graves' Hyperthyroidism from Animal Models Endocr. Rev., October 1, 2005; 26(6): 800 - 832. [Abstract] [Full Text] [PDF]

				Y. Oda, J. Sanders, S. Roberts, M. Maruyama, A. Kiddie, J. Furmaniak, and B. Rees Smith Analysis of Carbohydrate Residues on Recombinant Human Thyrotropin Receptor J. Clin. Endocrinol. Metab., June 1, 1999; 84(6): 2119 - 2125. [Abstract] [Full Text]

				M. Kita, L. Ahmad, R. C. Marians, H. Vlase, P. Unger, P. N. Graves, and T. F. Davies Regulation and Transfer of a Murine Model of Thyrotropin Receptor Antibody Mediated Graves' Disease Endocrinology, March 1, 1999; 140(3): 1392 - 1398. [Abstract] [Full Text]

				Y. Nagayama, H. Namba, N. Yokoyama, S. Yamashita, and M. Niwa Role of Asparagine-linked Oligosaccharides in Protein Folding, Membrane Targeting, and Thyrotropin and Autoantibody Binding of the Human Thyrotropin Receptor J. Biol. Chem., December 11, 1998; 273(50): 33423 - 33428. [Abstract] [Full Text] [PDF]

				B. Rapoport, G. D. Chazenbalk, J. C. Jaume, and S. M. McLachlan The Thyrotropin (TSH)-Releasing Hormone Receptor: Interaction with TSH and Autoantibodies Endocr. Rev., December 1, 1998; 19(6): 673 - 716. [Abstract] [Full Text]

				C. R. Da Costa and A. P. Johnstone Production of the Thyrotrophin Receptor Extracellular Domain as a Glycosylphosphatidylinositol-anchored Membrane Protein and Its Interaction with Thyrotrophin and Autoantibodies J. Biol. Chem., May 8, 1998; 273(19): 11874 - 11880. [Abstract] [Full Text] [PDF]

				Y. Osuga, S.-G. Liang, J. S. Dallas, C. Wang, and A. J. W. Hsueh Soluble Ecto-Domain Mutant of Thyrotropin (TSH) Receptor Incapable of Binding TSH Neutralizes the Action of Thyroid-Stimulating Antibodies from Graves' Patients Endocrinology, February 1, 1998; 139(2): 671 - 676. [Abstract] [Full Text] [PDF]